Total body irradiation before allogeneic bone marrow transplantation: is more dose better?

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1071-7. doi: 10.1016/s0360-3016(00)01491-7.

Abstract

Purpose: This study was performed to retrospectively assess the potential influence of total-body irradiation (TBI) dose on overall survival in patients undergoing allogeneic bone-marrow transplants (BMT) for hematologic malignancies.

Methods and materials: Between October 1984 and December 1996, 116 patients were conditioned with high-dose chemotherapy and fractionated TBI before allogeneic BMT. The median age was 34 years (range 3-60). The TBI dose was given in 6 fractions, twice-a-day, over 3 days before BMT. The total dose was 10 Gy in 24 patients, 12 Gy in 66 patients, and 13.5 Gy in 26 patients.

Results: TBI dose was inversely correlated with overall survival. Five-year survival was 62% for patients conditioned with 10 Gy, 55% for patients conditioned with 12 Gy, and 46% for patients conditioned with 13.5 Gy. Age at BMT was also independently correlated with survival, with the best outcome for patients < 40 years old.

Conclusion: A TBI dose (fractionated) > 10 Gy may not necessarily be associated with a better outcome in patients undergoing allogeneic bone-marrow transplant for hematologic malignancies.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Transplantation / methods
  • Bone Marrow Transplantation / mortality*
  • Busulfan / therapeutic use
  • Child
  • Child, Preschool
  • Cyclophosphamide / therapeutic use
  • Cytarabine / therapeutic use
  • Daunorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / mortality*
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / mortality*
  • Myelodysplastic Syndromes / therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Radiation-Sensitizing Agents / therapeutic use
  • Radiotherapy Dosage
  • Retrospective Studies
  • Thiotepa / therapeutic use
  • Transplantation Conditioning / methods
  • Transplantation Conditioning / mortality*
  • Transplantation, Homologous
  • Whole-Body Irradiation / methods
  • Whole-Body Irradiation / mortality*

Substances

  • Radiation-Sensitizing Agents
  • Cytarabine
  • Etoposide
  • Cyclophosphamide
  • Thiotepa
  • Busulfan
  • Daunorubicin